Primary Hyperlipidemia Therapeutics
1. Livalo patent expiration
Treatment: Adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with
LIVALO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753675 | KOWA CO | Quinoline analogs of mevalonolactone and derivatives thereof |
May, 2015
(10 years ago) | |
| US6465477 | KOWA CO | Stable pharmaceutical composition |
Dec, 2016
(9 years ago) | |
|
US5856336 (Pediatric) | KOWA CO | Quinoline type mevalonolactones |
Jun, 2021
(4 years ago) | |
| US5856336 | KOWA CO | Quinoline type mevalonolactones |
Jan, 2021
(5 years ago) | |
| US5854259 | KOWA CO | Quinoline type mevalonolactones |
Dec, 2015
(10 years ago) | |
| US7022713 | KOWA CO | Hyperlipemia therapeutic agent |
Feb, 2024
(1 year, 10 months ago) | |
| US8557993 | KOWA CO | Crystalline forms of pitavastatin calcium |
Feb, 2024
(1 year, 11 months ago) | |
|
US7022713 (Pediatric) | KOWA CO | Hyperlipemia therapeutic agent |
Aug, 2024
(1 year, 4 months ago) | |
|
US8557993 (Pediatric) | KOWA CO | Crystalline forms of pitavastatin calcium |
Aug, 2024
(1 year, 5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2014 |
| New Patient Population(NPP) | May 16, 2022 |
| Pediatric Exclusivity(PED) | Nov 16, 2022 |
Drugs and Companies using PITAVASTATIN CALCIUM ingredient
NCE-1 date: 16 November, 2021
Market Authorisation Date: 03 August, 2009
Dosage: TABLET
How can I launch a generic of LIVALO before it's drug patent expiration?
More Information on Dosage
LIVALO family patents
2. Welchol patent expiration
Treatment: Use as a bile acid sequestrant for lowering cholesterol; A method for reducing serum glucose levels in adults with type 2 diabetes mellitus; Use as a bile acid sequestrant
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5693675 | COSETTE | Alkylated amine polymers |
Dec, 2014
(11 years ago) | |
| US6784254 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US6433026 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US5607669 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Jun, 2014
(11 years ago) | |
| US5679717 | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Apr, 2014
(11 years ago) | |
| US7229613 | COSETTE | Method for lowering serum glucose |
Apr, 2022
(3 years ago) | |
| US6066678 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US5919832 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Apr, 2014
(11 years ago) | |
| US5917007 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US7101960 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
|
US5917007 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US5693675 (Pediatric) | COSETTE | Alkylated amine polymers |
Jun, 2015
(10 years ago) | |
|
US5679717 (Pediatric) | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Oct, 2014
(11 years ago) | |
|
US6066678 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US5607669 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Dec, 2014
(11 years ago) | |
|
US5919832 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Oct, 2014
(11 years ago) | |
|
US6433026 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US6784254 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US7101960 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US7229613 (Pediatric) | COSETTE | Method for lowering serum glucose |
Oct, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-608) | Oct 02, 2012 |
| Pediatric Exclusivity(PED) | Apr 02, 2013 |
| M(M-232) | Oct 20, 2024 |
Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient
Market Authorisation Date: 26 May, 2000
Dosage: CAPSULE; FOR SUSPENSION; TABLET; BAR, CHEWABLE
How can I launch a generic of WELCHOL before it's drug patent expiration?
More Information on Dosage
WELCHOL family patents
3. Zetia patent
expiration
Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in co...
ZETIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5846966 (Pediatric) | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar, 2014
(11 years ago) | |
| USRE42461 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(9 years ago) | |
| USRE37721 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(9 years ago) | |
|
USRE42461 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(8 years ago) | |
|
USRE37721 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(8 years ago) | |
| US7030106 | ORGANON | Sterol absorption inhibitor compositions |
Jan, 2022
(3 years ago) | |
|
US7030106 (Pediatric) | ORGANON | Sterol absorption inhibitor compositions |
Jul, 2022
(3 years ago) | |
| US5846966 | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep, 2013
(12 years ago) | |
| US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(2 months ago) | |
|
US7612058 (Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 05, 2011 |
| M(M-109) | Jan 24, 2015 |
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Dosage: TABLET
How can I launch a generic of ZETIA before it's drug patent expiration?
More Information on Dosage
ZETIA family patents